E-1-tri-n-Butylstannyl-4-dimethoxymethyl-4-trimethylsiloxy-1-octene

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: E-1-tri-n-Butylstannyl-4-dimethoxymethyl-4-trimethylsiloxy-1-octene
• 英文别名: E-1-tri-Butylstannyl-4-dimethoxymethyl-4-trimethylsiloxy-1-octene；[4-(Dimethoxymethyl)-1-tributylstannyloct-1-en-4-yl]oxy-trimethylsilane；[4-(dimethoxymethyl)-1-tributylstannyloct-1-en-4-yl]oxy-trimethylsilane
• 化学式: C₂₆H₅₆O₃SiSn
• 分子量: 563.524
• InChiKey: QWVSNVFEJDWSPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.72
• 重原子数：
  31
• 可旋转键数：
  20
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-dimethoxymethyl-4-trimethylsiloxy-1-octyne 、 三正丁基氢锡 在 偶氮二异丁腈 作用下， 生成 E-1-tri-n-Butylstannyl-4-dimethoxymethyl-4-trimethylsiloxy-1-octene
  参考文献：
  名称：

  15-Deoxy-16-hydroxy-16-formyo or dimethoxy-methyl-prostane derivatives

  摘要：

  本发明涉及具有C-16位被羟基、甲酰基或二甲氧甲基取代的E和F系列药理活性前列腺素，以及其药用可接受的、无毒的低烷基酯和盐，以及用于生产这些化合物的中间体和工艺。

  公开号：

  US04230879A1

文献信息

• 1-Substituted-1-oxo-prostane-derivatives of the E, A and F series
  申请人：American Cyanamid Company

  公开号：US04297516A1

  公开（公告）日：1981-10-27

  The invention disclosed herein relates to pharmacologically active prostaglandin derivatives of the E, F, or A series having on the terminal methylene carbon of the alpha chain, a substituent selected from the group consisting of: ##STR1## wherein R is C.sub.1 to C.sub.6 alkyl, and phenyl or phenyl substituted with one or more substituents selected from the group consisting of C.sub.1 -C.sub.4 alkyl, OR.sub.16, SR.sub.16, F, or Cl, and R.sub.16 is C.sub.1 to C.sub.6 alkyl.

  本发明公开的药物活性前列腺素衍生物属于E、F或A系列，在α链的末端亚甲基碳上有一个取代基，该取代基从以下组中选择：##STR1## 其中R是C.sub.1至C.sub.6烷基，和苯基或苯基，苯基上带有1个或多个取代基，该取代基从以下组中选择：C.sub.1-C.sub.4烷基，OR.sub.16，SR.sub.16，F或Cl，R.sub.16是C.sub.1至C.sub.6烷基。
• 15-Deoxy-16-hydroxy-16-formyo or dimethoxy-methyl-prostane derivatives
  申请人：American Cyanamid Company

  公开号：US04230879A1

  公开（公告）日：1980-10-28

  The invention disclosed herein relates to pharmacologically active prostaglandins of the E and F series in which C-16 is substituted with hydroxyl and formyl or dimethoxymethyl as well as the pharmaceutically acceptable, non-toxic lower alkyl esters and salts thereof, and to the intermediates and processes for producing such compounds.

  本发明涉及具有C-16位被羟基、甲酰基或二甲氧甲基取代的E和F系列药理活性前列腺素，以及其药用可接受的、无毒的低烷基酯和盐，以及用于生产这些化合物的中间体和工艺。
• 1-Hydroxymethyl-1-oxo-prostane-derivatives of the E, A and F-series
  申请人：American Cyanamid Company

  公开号：US04254036A1

  公开（公告）日：1981-03-03

  The invention disclosed herein relates to pharmacologically active prostaglandin derivatives of the E, F, or A series having on the terminal methylene carbon of the alpha chain a substituent selected from the group consisting of: ##STR1## wherein R is an alkyl group and R.sub.15 is C.sub.1 -C.sub.4 alkyl, di-C.sub.1 -C.sub.4 -alkylamino, C.sub.1 -C.sub.4 alkoxy, and phenyl or phenyl substituted with one or more substituents from the group consisting of C.sub.1 -C.sub.4, OR, SR, F, or Cl wherein R is as previously defined.

  本发明涉及具有在α链的末端亚甲基碳上选择自以下组成的取代基的E、F或A系列药理活性前列腺素衍生物：##STR1##其中R是烷基基团，R.sub.15是C.sub.1 -C.sub.4烷基，二C.sub.1 -C.sub.4-烷基氨基，C.sub.1 -C.sub.4烷氧基，苯基或苯基，其上取代基来自C.sub.1 -C.sub.4，OR，SR，F或Cl的组成，其中R如前所定义。